Treatment of recurrent Sweet’s syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept - 09/08/11
Plan
This case series was investigator initiated. Financial support for the manuscript was provided by Amgen Inc and by Wyeth Research. Conflicts of interest: Dr Jackson has received research honoraria and/or consulting support from Abbott, Amgen, Biogen, Genentech, Centocor, Novartis, Ferndale, Connetics, CollaGenex, and Roche. Dr Turner has no disclosures to report. Dr Yamauchi is on the Amgen speakers board and is a consultant and investigator for Amgen but owns no Amgen stock. Dr Lowe is on the Amgen speakers board but owns no Amgen stock. Dr Gindi has no conflict of interest to disclose. Reprints not available from the authors. |
Vol 54 - N° 3S2
P. S122-S126 - mars 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?